A case study of voltage-gated potassium channel antibody-related limbic encephalitis with PET/MRI findings

Brian K. Day
Washington University School of Medicine in St. Louis
Lawrence Eisenman
Washington University School of Medicine in St. Louis
Joseph Black
Washington University School of Medicine in St. Louis
Luigi Maccotta
Washington University School of Medicine in St. Louis
R. Edward Hogan
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Day, Brian K.; Eisenman, Lawrence; Black, Joseph; Maccotta, Luigi; and Hogan, R. Edward, "A case study of voltage-gated potassium channel antibody-related limbic encephalitis with PET/MRI findings." Epilepsy & Behavior Case Reports. 4, 23-26. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/5809

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Case Report

A case study of voltage-gated potassium channel antibody-related limbic encephalitis with PET/MRI findings

Brian K. Day *, Lawrence Eisenman, Joseph Black, Luigi Maccotta, R. Edward Hogan

Department of Neurology, Washington University in St. Louis, Campus Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110, USA

A R T I C L E   I N F O

Article history:
Received 11 December 2014
Received in revised form 27 January 2015
Accepted 4 February 2015
Available online 6 June 2015

Keywords:
Voltage-gated potassium channel
Limbic encephalitis
Autoimmune epilepsy
Positron emission tomography
Magnetic resonance imaging
PET/MRI

A B S T R A C T

Preclinical and clinical studies have demonstrated the significance of inflammation and autoantibodies in epilepsy, and the use of immunotherapies in certain situations has become an established practice. Temporal lobe epilepsy can follow paraneoplastic or nonparaneoplastic limbic encephalitis associated with antibodies directed against brain antigens. Here, we focus on a patient with worsening confusion and temporal lobe seizures despite treatment with antiepileptic medications. Serial brain MRIs did not conclusively reveal structural abnormalities, so the patient underwent brain PET/MRI to simultaneously evaluate brain structure and function, revealing bitemporal abnormalities. The patient was diagnosed with voltage-gated potassium channel antibody-related limbic encephalitis based on clinical presentation, imaging findings, and antibody testing. Treatment included the addition of a second antiepileptic agent and oral steroids. His seizures and cognitive deficits improved and stabilized.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The detection of novel autoantibodies has provided etiological insight into epileptic disorders of previously unknown causes. Forerunners in this area of investigation include voltage-gated potassium channel (VGKC) antibodies, antibodies against the N-methyl-D-aspartate receptor (NMDAR), and antibodies against glutamic acid decarboxylase (GAD). Other noteworthy antibodies include those against AMPA receptors and the GABAA receptor as well as against onconeural antigens [1,2]. Often, the diagnosis of an autoimmune-related epileptic disorder is made during the evaluation of an acute limbic encephalitis (LE), at times within the setting of drug-resistant status epilepticus. However, autoantibody testing has also returned positive results during the recovery phase of an apparent monophasic illness with acute seizures or in patients with less severe chronic epilepsy [3]. At times, the positive antibodies are not clearly directly causative for seizures but may be nonspecifically raised and serve as immune markers, implicating that there is a significant inflammatory component. The discovery of autoantibodies typically triggers a neoplasic evaluation. For example, a significant subset of patients diagnosed with anti-NMDAR encephalitis is found to have ovarian teratomas, which are therapeutically removed [3]. But in many cases, these antibodies are nonparaneoplastic, and immunotherapy may be the only major intervention along with antiepileptic medications.

We describe a clinical case in which the use of antibody testing and PET/MRI imaging aided in the identification of voltage-gated potassium channel antibody-related limbic encephalitis (VGKC-LE). Magnetic resonance imaging findings alone did not definitively demonstrate structural abnormalities, even when repeated over time, despite clinical observations that his memory and cognition were progressively worsening. In addition to antibody testing, brain PET was obtained to evaluate for regions of hypometabolic abnormalities that might have gone underappreciated with separately acquired single modality tests. Areas of differential metabolism or ligand specificity on PET can be examined more carefully for structural identification and analysis using MRI, and the limitations that currently exist for the

http://dx.doi.org/10.1016/j.ebcr.2015.02.002
2213–3232/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
resolution of PET images can be minimized by the much better spatial resolution afforded by immediate, precise coregistration of the MRI [5]. We present the PET/MRI images to showcase this novel technology and to present findings in a patient suffering from VGKC-LE.

2. Materials and methods

A single patient underwent an inpatient evaluation which included a comprehensive paraneoplastic panel and brain PET/MRI imaging using a Siemens Biograph mMR system. Visual analysis of the imaging was performed by neuroradiologists.

3. Case report

A 64-year-old, right-handed man presented in referral for an 11-month history of seizures. Witnessed episodes during wakefulness included behavioral arrest, staring, and confusion lasting minutes, which had progressively increased in frequency to multiple per day. He also had nocturnal episodes of arousal, moaning, repetitive hand movements, and confusion lasting seconds. The patient had no memory of these events. Despite initial treatment with levetiracetam, titrated to 2000 mg twice daily, he continued to have worsening memory, behavioral changes, difficulty paying bills, and trouble navigating his own home. His personality changed from reserved to outgoing.

Extensive evaluation 6 months from onset, including head CT, CBC, CMP, UA, vitamin B12 testing, thyroid testing, coagulation profile, creatine kinase, and CSF HSV-1 PCR, was unremarkable. A lumbar puncture showed elevated protein at 72 mg/dL, and EEG revealed left frontotemporal epileptiform abnormalities. An initial brain MRI with contrast and another repeated four months later showed possibly increased T2-weighted signal in the bilateral medial temporal lobes and insular cortex. However, the appearance of these areas did not significantly change over time despite his progressively worsening symptoms (Fig. 1).

During reevaluation on presentation to our institution, a repeat lumbar puncture again showed elevated protein at 72 mg/dL without other abnormalities. Video-EEG captured bitemporal seizures and epileptiform discharges. Brain PET/MRI revealed bitemporal and bilateral insular hypometabolism (Fig. 2). Voltage-gated potassium channel antibodies were present. Otherwise, extensive infectious, autoimmune, neoplastic, paraneoplastic, prion disease workup, CT of the chest, abdomen, and pelvis, and body MRI were unrevealing. Treatment included the addition of lamotrigine as a second antiepileptic agent and oral

![Fig. 1](image1.png)

**Fig. 1.** Axial T2/FLAIR images obtained four months apart at the level of the temporal lobes (A. initial, B. follow-up) and insula (C. initial, D. follow-up). The somewhat increased signal bilaterally in the mesial temporal structures and insula was present, but not definitively abnormal, and did not significantly change over time.
steroids (prednisone 1000 mg each weekend for 8 weeks, then every other weekend for 8 doses). His seizures and cognitive deficits improved and stabilized.

4. Discussion

This patient presented with a clinical picture of medically refractory temporal lobe epilepsy complicated by memory and cognitive problems. The majority of testing was unrevealing, and even brain MRI repeated over time did not show any definitive structural abnormalities to support an active region-specific pathological process. As the patient’s behavior and thinking progressively worsened, the possibility of an ongoing limbic encephalitis was evaluated by comprehensive paraneoplastic antibody panel and advanced brain imaging. Brain PET/MRI technology, available at our institution, afforded us the opportunity to repeat the brain MRI once more while also simultaneously assessing for functional abnormalities using PET. The PET/MRI findings proved to be key supportive evidence of bilateral temporal and insular abnormalities where serial MRI had fallen short. Although bilateral hypometabolism in these regions is not specific for limbic encephalitis and could be seen in patients with other forms of temporal lobe epilepsy, the PET/MRI results were concordant with the clinical suspicion. These results along with positive VGKC antibodies clarified the diagnosis and improved confidence in moving forward with both additional antiepileptic treatment and immunotherapy, which ultimately kept the patient seizure-free and significantly improved his cognition.

Voltage-gated potassium channel antibody-related limbic encephalitis typically includes encephalopathy, seizures, and mesial temporal lobe structural abnormalities [7–10]. Classically, regional abnormalities in the mesial temporal lobes in VGKC-LE are not seen in other VGKC antibody-related neurological disorders, namely Morvan’s or Isaac’s syndromes [11]. Imaging abnormalities typical of VGKC-LE have also

Fig. 2. A. and D. Axial T2/FLAIR MRI at the level of the temporal lobes and insula, respectively, with possible mesial temporal and insular hyperintensities; C. and F. FDG-PET images at these levels showing bitemporal and bilateral insular hypometabolism; B. and E. Coregistered MRI and PET at these levels, showing where the areas of hypometabolism align with the detailed neuroanatomy.
been reported in patients manifesting personality changes and memory deficits without evidence of seizures [12,13]. Furthermore, patients with VGKC-LE have been reported to have a normal brain MRI but bitemporal hypometabolism on brain PET [14], similar to findings in our patient.

This is the first study reporting PET/MRI findings in VGKC-LE. However, correlations of PET and MRI in VGKC-LE have previously been described. In seven patients with subacute limbic encephalitis, one with VGKC antibodies, the authors reported that the neuroimaging findings of PET and MRI did not overlap in half the patients but, when combined, revealed temporal pathology in all of them [15]. One patient with VGKC-LE had serial brain MRI and PET studies for two years, revealing a successive switch in prominence from right to left mesial temporal lobe changes. Of special relevance to the case presented, the PET findings were prominent earlier than the MRI findings during the development of left mesial temporal pathology, despite over a year of seizures prior to that time [16].

5. Conclusions

In this case report, the use of brain PET/MRI and antibody testing aided in the diagnosis of VGKC-LE. Antibody testing should be considered in cases of acute epilepsies of unknown cause, especially if they are drug-resistant or severely debilitating. Brain PET and MRI are complementary technologies for assessing regional abnormalities, and brain PET may reveal focal findings in patients with VGKC-LE missed by brain MRI alone. Simultaneous brain PET/MRI multimodal technology has synergistic potential for identifying focal abnormalities that separately-acquired single modality testing might miss.

Conflict of interest

There is no conflict of interest.

References

[1] Yu N, Liu H, Di Q. Modulation of immunity and the inflammatory response: a new target for treating drug-resistant epilepsy. Curr Neuropharmacol 2013;11(1):114–27.

[2] Granata T, Cross H, Theodore W, Avanzini G. Immune-mediated epilepsies. Epilepsia 2011;52(Suppl. 3):5–11.

[3] Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 2011;52(Suppl. 3):18–22.

[4] Kolb A, Wehrl HF, Hofmann M, Jendrohofer MS, Eriksson L, Ladebeck R, et al. Technical performance evaluation of a human brain PET/MRI system. Eur Radiol 2012;22(8):1776–88.

[5] Cho ZH, Son YD, Choi EJ, Kim HK, Kim JH, Lee SY, et al. In-vivo human brain molecular imaging with a brain-dedicated PET/MRI system. MAGMA Feb. 2013;26(1):71–9.

[6] Pichler BJ, Jendrohofer MS, Plockenborn C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008;185(Pt 1):109–32.

[7] Irani SR, Alexander S, Waters P, Kloeppa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133(9):2734–48.

[8] Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124( Pt 12):2417–26.

[9] Irani SR, Pettingill P, Kloeppa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72(2):241–55.

[10] Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin 2010;28(4):941–59.

[11] Josephs KA, Silber MH, Fealey RD, Nippoldt TB, Auger RG, Vernino S. Neurophysiologic studies in Morvan syndrome. J Clin Neurophysiol 2004;21(6):440–5.

[12] Saccardi T, Pedrono J, Bernardino T, Barsottini OC, Ferraz HB. Subacute cognitive impairment, hyponatremia and mesial temporal lobe lesions: a typical presentation of voltage-gated potassium channel (VGKC) antibody-associated limbic encephalitis. Arq Neuropsiquiatr 2011;59(6):980–1.

[13] Harrower T, Polynyne T, Kartsounis L, De Silva RN, Hodges JR. A case of voltage-gated potassium channel antibody-related limbic encephalitis. Nat Clin Pract Neurol 2006; 2(6):339–43 [quiz following 343].

[14] Gast H, Schindler K, ZGraggen WJ, Hess CW. Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy. Epilepsy Behav 2010;17(4):555–7.

[15] Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropsychological testing: MRI and PET correlates. Brain 2005;128(Pt 8):1764–77.

[16] Chatzikostantinou A, Szabo K, Ottomayer C, Kern R, Hennerici MG. Successive affection of bilateral temporomesial structures in a case of non-paraneoplastic limbic encephalitis demonstrated by serial MRI and FDG-PET. J Neurol 2009;256(10):1753–5.